Thursday, May 29, 2014
Grand Hyatt New York
109 E 42nd Street
New York, NY 10017
Below is a partial list of the companies that will be presenting.
Abtech Holdings, Inc. (ABHD)
AbTech is an environmental company dedicated to providing innovative solutions to clean water. As the developer and manufacturer of Smart Sponge® and Smart Sponge® Plus technology, AbTech provides an effective, low cost solution that solidifies, separates and removes contaminants including hydrocarbons, sediment and other foreign elements found in storm water, produced water and industrial waste water. These contaminants endanger ponds, lakes, streams, rivers, oceans, drains, and pipe outflows - creating public and environmental health concerns. The AbTech solutions not only treat water for a clean discharge, but also can be used to recycle water for re-use. The SmartSponge technology has secured 17 U.S. patents, 16 international patents and, following a three year regulatory approval process, has an antimicrobial product registered with the EPA (EPA Registration # 86256-1) for outdoor use to reduce coliform bacteria, a pathogen. An added benefit of Smart Sponge is its sustainable end-of-life use. Once saturated with contaminants and in need of replacement, the spent sponge is a significant energy source as it has a very high BTU value and can be burned as fuel.
Acorn Energy, Inc. (ACFN)
Acorn Energy, Inc. is a holding company whose four portfoilo companies help their customers achieve greater productivity, reliability, security, and efficiency - all of which leader to greater profitability. GridSense - provides monitoring for all critical points along the electricity delivery system. OMNIMETRIX - remotely monitors emergency back-up power generation systems to increase reliability. US Seismic - supplies fiber optic sensing solutions to increase oil/gas production and lower costs. DSIT - provides security solutions from underwater threats to marine based energy assets.
AdCare Health Systems, Inc. (ADK)
AdCare Health Systems, Inc.is a recognized innovator in senior living and health care facility management. AdCare, through its subsidiaries, owns and operates fifty skilled nursing and assisted living facilities in eight states. The Company has grown rapidly in recent years having increased revenues approximately ten-fold since 2010. Since its inception in 1988, AdCare's mission has been to provide quality healthcare services to the elderly.
Alteva is a premier provider of hosted Unified Communications as a Service (UCaaS) that significantly enhances business productivity and efficiency. Alteva’s UCaaS solution integrates and optimizes best-in-class cloud-based technologies and business applications to deliver a comprehensive voice, video and collaboration service for the office and mobile workforce. Alteva is committed to delivering meaningful value to its customers through a consistent, high quality and unified user experience across multiple devices, platforms and operating systems. These attributes have positioned Alteva as a leading hosted communications provider and the partner of choice for a growing number of business customers nationwide and internationally.
Amarantus BioScience, Inc. (AMBS)
Amarantus BioScience, Inc. is a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis (programmed cell death). The Company’s lead therapeutic program MANF is a disease-modifying under development for Parkinson's disease and other apoptosis-related disorders. The Company's lead diagnostic program, LymPro®, is aimed at developing a diagnostic blood test for Alzheimer's disease.
Aspen Group, Inc. (ASPU)
Aspen Group, Inc. is an online post-secondary education company. Aspen University’s mission is to become an institution of choice for adult learners by offering cost-effective, comprehensive, and relevant online education. We are dedicated to helping our students exceed their personal and professional objectives in a socially conscious and economically sensible way. One of the key differences between Aspen and other publicly-traded, exclusively online, for-profit universities is that 87% of our full-time degree-seeking students (as of March 31, 2013) are enrolled in a graduate degree program (master’s or doctoral degree program). Aspen is dedicated to providing the highest quality education experiences taught by top-tier faculty - 67% of our adjunct faculty holds doctoral degrees.
Asure Software, Inc. (ASUR)
Asure Software, Inc., headquartered in Austin, Texas, offers cloud-based time and labor management and workspace management solutions that enable businesses to control their biggest costs -- labor, real estate and technology -- and prepare for the workforce of the future in a highly mobile, geographically disparate and technically wired work environment. Asure serves approximately 6,000 clients worldwide and currently offers two main product lines: AsureSpace™ workplace management solutions enable organizations to maximize the ROI of their real estate, and AsureForce® time and labor management solutions deliver efficient management of human resource and payroll processes
Atossa Genetics, Inc. (ATOS)
Atossa Genetics is a health care company focused on the prevention of breast cancer through the commercialization of diagnostic medical devices and laboratory developed tests that can detect precursors to breast cancer, and through the research, development, and ultimate commercialization of treatments for pre-cancerous lesions and ductal carcinoma in situ, or DCIS. The Company’s leading diagnostic test, the ForeCYTE Breast Health Test, consists of a patented medical device that can collect fluid samples from the breast milk ducts, where over 95% of breast cancers arise. These samples are processed at Atossa’s wholly-owned, CLIA-certified, National Reference Laboratory for Breast Health, and a report is generated for the doctor and patient. The ForeCYTE Test was launched in January 2013 through Clarity Women’s Health and major medical device distributors who collectively have 5,000 sales reps calling on 33,000 OB/GYNs nationwide.
Augme® Technologies, Inc (AUGT)
Augme® Technologies, Inc. provides strategic services and mobile marketing technology to leading consumer and healthcare brands. Selling its products and services under the Hipcricket® brand, Augme's platform has provided measurable successes across an industry-leading 175,000 campaigns for its clients, which include many of America's brand-name leaders (e.g., Macy's, MillerCoors, Nestle, Clear Channel) in a variety of industries, along with their agencies. Augme's offerings allow marketers, brands, and agencies to plan, create, test, deploy, and track mobile marketing programs across every mobile channel, including SMS, MMS, 2D/QR codes, mobile websites, advertising networks, social media and branded apps. Augme's platforms facilitate consumer brand interaction and the ability to track and analyze campaign results. Using its own patented device-detection and proprietary mobile content adaptation software, AD LIFE® solves the mobile marketing industry problem of disparate operating systems, device types, and on-screen mobile content rendering.
Axion Power International, Inc. (AXPW)
Axion has developed and patented a next generation energy storage device that won the prestigious Frost & Sullivan Technology Award for North America in the field of lead-acid batteries. According to Frost & Sullivan, Axion's new PbC® batteries have "the potential to revitalize the lead-acid battery industry by breathing new life into an established technology that is not well suited to the requirements of important new applications like hybrid electric vehicles and renewable power."
Axion Power International, Inc. is the industry leader in the field of lead-carbon energy storage technologies. Axion believes this new battery technology is the only class of advanced battery that can be assembled on existing lead-acid battery production lines throughout the world utilizing Axion’s proprietary carbon electrodes. Axion's future goal, after filling their plant's lead-carbon battery production capacity, is to become the leading supplier of carbon electrode assemblies for the global lead-acid battery industry.
BioDrain Medical, Inc. (BIOR)
BioDrain Medical, Inc. has a fully automated, patented, FDA cleared, surgical fluid disposal system that virtually eliminates operating room workers' exposure to blood, irrigation fluid and other potentially infectious fluids found in the surgical environment. Today's manual surgical fluid handling methods of hand-carrying filled surgical fluid canisters and emptying these canisters is an exposure risk and an antiquated approach to the handling of surgical fluid waste. BioDrain's STREAMWAY System fully automates the collection, measurement and disposal of surgical fluids and is designed to result in: 1) reducing overhead costs to hospitals and surgical centers, 2) improving Occupational State and Health Association (OSHA) and other regulatory compliance agencies' safety concerns, and 3) streamlining the efficiency of the operating room (and thereby making surgeries more profitable).
BioDrain's STREAMWAY System is eco-friendly as it contributes to cleaning up the environment. Currently, approximately 50 million bloody, potentially disease infected canisters go to landfills annually in the United States. These tainted canisters can remain in landfills for years to come. With the installation of BioDrain's STREAMWAY System, the number of canisters can be significantly reduced. BioDrain Medical, Inc. makes the operating room and our environment safer, cleaner, and better.
BioDrain products are currently being represented by independent professional sales representatives that cater to the needs of hospitals and ambulatory surgical centers across the country.
BioRestorative Therapies, Inc. (BRTXD)
BioRestorative Therapies, Inc. (“BRT”) develops medical procedures using cell and tissue protocols, primarily involving adult stem cells, designed for patients to undergo minimally invasive cellular-based treatments. BRT is developing the following scientific initiatives:
- brtxDISC™ Program (Disc Implanted Stem Cells), a non-surgical treatment for bulging and herniated discs that addresses the gap between non-invasive and invasive back procedures. This research is still in the non-clinical, investigational stage.
- ThermoStem®Program, a treatment for metabolic disorders (diabetes, heart disease, etc.) and obesity using brown fat stem cells. Initial non-clinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels in the body.
- brtx-C Cosmetic Program, based on the development of a human cellular extract that, per initial in vitrostudies, when applied to human skin cells, appears to cause an increase in the production of collagen and fibronectin, which are proteins that are essential to combating the aging of skin. Potential cosmetic uses are being explored with third parties.
Blue Calypso Inc. (BCYP)
Blue Calypso is an innovator in digital word-of-mouth marketing and advertising. With Blue Calypso¹s patented platform, brands can harness the power of friend-to-friend referrals by empowering their advocates to share brand content with their social media communities and rewarding them for sharing their influence. Through robust, real-time analytics, brands can achieve a measurable ROI against their social media investment, acquire high-value customers and increase sales.
BOLDFACE Group Inc. (BLBK)
BOLDFACE Group, Inc. was formed to secure and create licensing opportunities with top tier celebrities and brands. Boldface launched with its founding license for Kardashian Beauty and has secured retail distribution in over 4,100 locations to date with a strong international roll out ahead. In addition, the Boldface has also secured licenses with Mario Lopez, in the fragrance category, and UGLYDOLL, in the personal care category. BOLDFACE will continue to add strong brands into the company while maintaining and growing the founding licenses. BOLDFACE achieved gross and net revenues of $5.3M and $4.6M as of FY Q3 2013.
BOLDFACE was founded by Nicole Ostoya and Robin Coe Hutshing - beauty industry veterans, bringing deep expertise in fragrance, color and personal care product development in multiple channels of distribution from prestige to mass - as well as access to celebrities of all levels. The BOLDFACE team has created beautiful brands and products in all areas of
beauty and also boasts a disciplined control on cost of goods to maximize both impact and profit.
Caliber Imaging & Diagnostics, Inc. (LCDX)
CaliberI.D’s imaging technology platform, the Vivascope®, introduces researchers and clinicians to a powerful new world in which cells can be viewed and analyzed without a biopsy.
Cancer Genetics, Inc. (CGIX)
Cancer Genetics, Inc. (CGI) is an emerging leader in DNA-based cancer diagnostics and services some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also provide a comprehensive range of non-proprietary oncology-focused tests and laboratory services.
CGI’s cutting-edge proprietary tests and state- of-the-art reference laboratory provide critical genomic information to healthcare professionals as well as biopharma and biotech. Our state of the art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State.
Founded in 1999 by world-renowned cytogeneticist Dr. R.S.K. Chaganti, the Company has been built on a foundation of world-class scientific knowledge and IP in solid and blood-borne cancers, and has established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic and the National Cancer Institute.
Can-Fite BioPharma (CANFY)
Can-Fite BioPharma is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary compounds in phase 2 and 3 clinical development stage, which address autoimmune-inflammatory cancer and ophthalmic (through 82% holding in OphthaliX - OPLI) diseases.
The company platform technology utilizes the Gi protein associated A3 adenosine receptor (A3AR) as a therapeutic target. A3AR is highly expressed in inflammatory and cancer cells where low expression is found in normal cells, suggesting that the receptor could be a unique target for pharmacological intervention. The company compounds bind with nM affinity to the A3AR and initiate de-regulation of the NF-?B and the Wnt signal transduction pathways resulting in anti-inflammatory and anti-cancer effects.
The company pipeline drugs are synthetic, highly specific agonists and allosteric modulators targeting the A3AR. All drugs are orally bioavailable with an excellent safety profile. CF101 drug candidate is in advanced clinical development for the treatment of autoimmune-inflammatory diseases, including Rheumatoid Arthritis (phase 2b) and Psoriasis (phase 2/3). Can-Fite holds 82% in OphthaliX Inc. (OPLI) which develops CF101 for ophthalmic indications, including Dry Eye Syndrome (phase 3), Glaucoma (phase 2) and Uveitis. CF102 drug candidate is being developed for the treatment of Hepatocellular Carcinoma (Primary Liver Cancer), under an Orphan Drug Status designated by the FDA. CF602 is Can-Fite’s second generation allosteric drug candidate which has shown proof of concept in in vitro and in vivo studies.
Can-Fite has a wealth of clinical experience with over 1,000 patients who have participated in clinical trials conducted by the company.
Can-Fite has licensed CF101 for the treatment of autoimmune diseases to Seikagaku Corporation (SKK) in Japan and for RA to Kwang Dong in Korea.
CAS Medical Systems, Inc. (CASM)
CASMED is a leading developer and manufacturer of medical devices for non-invasive patient monitoring. The Company's FORE-SIGHT Absolute Cerebral Oximeter provides a highly accurate, non-invasive, continuous measurement of absolute cerebral tissue oxygen saturation. Direct monitoring of tissue oxygenation provides a superior and powerful tool to alert clinicians to otherwise unrecognized and dangerously low levels of oxygenation of the brain and other tissues, thereby allowing them to intervene appropriately in the care of their patients. In addition to FORE-SIGHT Oximeters and accessories, the Company provides a line of bedside patient vital signs monitoring products, proprietary non-invasive blood pressure monitoring solutions for OEM use, neonatal intensive care supplies, and service. CASMED products are designed to provide unique monitoring solutions that are vital to patient care.
Cel-Sci Corp (CVM)
CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system. Its lead investigational therapy is Multikine (Leukocyte Interleukin, Injection), currently being studied in a pivotal global Phase III clinical trial. Multikine is the first immunotherapeutic agent being developed as a potential first-line treatment for advanced primary head and neck cancer. CEL-SCI is also investigating an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized patients and as a vaccine (CEL-2000) for Rheumatoid Arthritis (currently in preclinical testing) using its LEAPS technology platform. The investigational immunotherapy LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu, as CEL-SCI scientists are very concerned about the possible emergence of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.
Chanticleer Holdings Corp (HOTR)
Chanticleer Holdings (hereinafter “HOTR”) currently has exclusive franchise rights to open and operate HOOTERS® restaurants in parts of Brazil, as well as all of South Africa and Hungary. Additionally, we have joint ventured with the owner of exclusive HOOTERS® franchise rights in Australia.
HOTR owns in whole or part of six HOOTERS® restaurants in its international territories (4 in South Africa, 1 in Australia, and 1 in Hungary).
HOTR also has a minority ownership interest in the privately held parent company of the HOOTERS® brand, Hooters of America (HOA). HOTR’s CEO and President, Michael Pruitt, is a member of the HOA Board of Directors.
China Distance Education Holdings Limited (CDEL)
China Distance Education Holdings Limited is a leading provider of online education in China focusing on professional education. The online courses offered by the Company are designed to help professionals and other course participants obtain and maintain the skills, licenses and certifications necessary to pursue careers in China in the areas of accounting, law, healthcare, construction engineering, and other industries. The Company also offers online test preparation courses to self-taught learners pursuing higher education diplomas or degrees and to secondary school and college students preparing for various academic and entrance exams. In addition, the Company offers online foreign language courses and offline business start-up training courses.
Chromadex Corporation (CDXC)
ChromaDex® is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries. Our pipeline of proprietary products include patented and clinically studied pTeroPure® pterostilbene; ProC3G™, a natural black rice extract containing ~35% cyanidin-3-glucoside; pteroberry™, an all-natural blend of pterostilbene and organic berry extracts; nutraGac™, a Gac fruit powder with high concentrations of Lycopene and ß-carotene; PURENERGY™, a caffeine product that is the fushion of pTeroPure and caffeine and Nicotinamide Riboside, a novel next-generation B-vitamin currently under development. All products are backed with extensive scientific research and intellectual property.
Circadian Technologies Limited (CIR)
Circadian Technologies Limited is an Australian biotechnology company focused on the development of biologics-based therapies for the treatment of cancer and eye disease. Circadian owns an extensive patent portfolio covering targets (VEGF-C, VEGF-D, VEGFR-3) and drugs (VGX-100 and VGX-300) to modulate the processes of angiogenesis - the development of blood vessels within the body and lymphangiogenesis -the development of lymphatics in the human body.
Circadian's product pipeline includes biologics drugs targeting important mediators of angiogenesis and lymphangiogenesis. Circadian's lead development candidate, VGX-100, is a fully human antibody that inhibits the VEGF-C protein. VGX-100 is currently in Phase 1a and Phase 1b clinical trials in late stage cancer patients at 2 leading US cancer centres. These studies are being done under an IND. Phase 2 studies are expected to commence in H2 2013.
VGX-100 and VGX-300 are also being developed as agents to treat age related macular degeneration in patients non-responsive to anti-VEGF-A therapy. VEGF-C and VEGFR-3 have been shown to play a major role in retinal angiogenesis. VGX-100 and VGX-300 have been shown to be effective in animal models of back of the eye disease. They are currently in pre-clinical development with clinical development expected to commence by H1 2014.
Cleveland BioLabs, Inc. (CBLI)
Cleveland BioLabs, Inc. is a clinical-stage biotechnology company developing a robust pipeline of compounds primarily focused on oncology applications and mitigation of radiation injury. Our lead compound, Entolimod™ (CBLB502), is being developed as both a radiation countermeasure and a cancer treatment. CBLI has two operating subsidiaries, Incuron, LLC, and Panacela Labs, Inc., and strategic relationships with the Cleveland Clinic, Roswell Park Cancer Institute, the Children’s Cancer Institute Australia and the Armed Forces Radiobiology Research Institute.
CopyTele, Inc. (COPY)
CTI’s new business model is the monetization and assertion of patents. Since announcing our new business model in October of 2012, the company has launched 2 patent assertion campaigns: one involving patents from CTI’s Key Based Encryption patent portfolio, and the other involving patents from CTI’s ePaper® Electrophoretic Display patent portfolio. Each assertion campaign has the potential to generate significant revenue for the company. In addition, the company has recently acquired the rights to two additional patent portfolios, bringing the total number of monetizeable portfolios owned or controlled by the company to 6.
CTI’s new management team has over 30 years of combined experience in Patent Monetization and Patent Assertion, and has generated in excess of $150 million patent licensing revenues. CTI’s current patent portfolios include: Key Based Encryption, E-Paper® Electrophoretic Display, Nano Field Emission Display (“NFED”), Micro Electro Mechanical Systems Display (“MEMS”), Loyalty Conversion Systems, and Window Frame Construction.
CUI Global (CUI)
CUI Global is a publicly traded platform company dedicated to maximizing shareholder value through the acquisition and development of innovative companies and technologies. From its Vergence GasPT2 platform targeting the energy sector, to its subsidiary CUI Inc's industry leading digital power platform targeting the networking and telecom industries, CUI Global has built a diversified portfolio of industry leading technologies that touch many markets. As a publicly traded company, shareholders are able to participate in the opportunities, revenues, and profits generated by the products, technologies, and market channels of CUI Global and its subsidiaries. CUI Global prides itself on operating with the same level of integrity, respect, and philanthropic dedication that was put in place by CUI Inc's founder more than 20 years ago. It is these values that allow the company to make a difference in the lives of their customers, their community, their employees, and their investors.
Recently, a move was made to merge and streamline resources with its subsidiary CUI Inc in order to create a unified, international brand that now positions CUI Global for further strategic expansion.
Coronado Biosciences Inc. (CNDO)
Coronado is a biopharmaceutical company focused on novel immunotherapy biologic agents for autoimmune diseases and cancer. Coronado's two principal pharmaceutical product candidates are initially targeted for clinical development for inflammatory bowel disease, multiple sclerosis and acute myeloid leukemia.
Cyalume Technologies Holdings, Inc. (CYLU)
Cyalume designs and manufactures non-pyrotechnic tactical products and training solutions for the world's militaries and law enforcement agencies, as well as for certain safety markets. Cyalume is the exclusive supplier to the U.S. and NATO-country militaries for all of their chemical light needs and operates manufacturing facilities in the U.S. and France. Through its subsidiary Cyalume Specialty Products, Cyalume also manufactures specialty chemical components for various markets.
CytoSorbents Corporation (CTSO)
CytoSorbents Corporation is a critical care focused therapeutic device company working to prevent or treat organ failure using blood purification in patients in the intensive care unit. Organ failure occurs when vital organs like the lungs, heart and kidneys stop functioning and remains one of the greatest and most costly unmet medical needs in modern medicine, costing millions of lives and billions of dollars each year. Organ failure accounts for nearly half of all deaths in the intensive care unit from any cause, with supportive care therapy to keep patients alive, but little to nothing to help patients recover. CytoSorbents European Union approved flagship product, CytoSorb®, is designed to reduce the massive production of inflammatory toxins, called “cytokine storm”, that is a key driver of organ failure. The underlying purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids. These beads form the basis of a strong pipeline of products under development, such as HemoDefend, ContrastSorb, and others. The technology is covered by 32 issued U.S. patents and has the support of key government organizations such as DARPA and the US Army.
Dr. Phillip Chan is the CEO and President of CytoSorbents Corporation. Prior to CytoSorbents, Dr. Chan led healthcare and life science investments as Partner for the $80M NJTC Venture Fund. He was responsible for numerous investments in therapeutics, medical devices and diagnostics. Dr. Chan also co-founded Andrew Technologies, a venture-backed medical device company commercializing its FDA approved HydraSolve™ lipoplasty system for body countouring. Dr. Chan is a Board-certified internal medicine physician and completed his residency at Harvard Medical School at the Beth Israel Deaconess Medical Center. Dr. Chan received his MD/PhD from Yale University School of Medicine and his BS in cell and molecular biology from Cornell University.
CytRx Corporation (CYTR)
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The CytRx oncology pipeline includes two programs in clinical development for cancer indications: aldoxorubicin (formerly known as INNO-206) and tamibarotene. With its tumor-targeted doxorubicin conjugate aldoxorubicin, CytRx has initiated an international Phase 2b clinical trial as a treatment for soft tissue sarcomas, has completed its Phase 1b/2 clinical trial primarily in the same indication, and has initiated a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors and a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors. The Company has held a positive meeting with the FDA to discuss a potential Phase 3 pivotal trial with aldoxorubicin as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy, and has submitted a special protocol assessment related to this trial. Tamibarotene is being tested in a double-blind, placebo-controlled, international Phase 2b clinical trial in patients with non-small-cell lung cancer. The Company reached its enrollment target for that trial in February 2013. The Company completed its evaluation of a third drug candidate, bafetinib, in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL), and plans to seek a partner for further development of bafetinib.
DDD Group Plc (DDD)
DDD transforms the visual experience by bringing 3D to the consumer. Its TriDefTM 3D solutions convert 2D to 3D automatically, and enable delivery to 3D TVs, PCs and mobile devices. Leading brands including Intel, Samsung, LG Electronics and Sony license these solutions. Over 26 million TriDef 3D products have been shipped by DDD’s licensees worldwide. DDD’s Yabazam! label delivers 3D everywhere with its online content portal and Smart TV apps. DDD’s shares are quoted on the London Stock Exchange’s AIM Market.
DecisionPoint Systems, Inc. (DPSI)
DecisionPoint Systems, Inc. delivers improved productivity and operational advantages to its clients by helping them move their business decision points closer to their customers. They do this by making enterprise software applications accessible to the front-line worker anytime, anywhere. DecisionPoint utilizes all the latest wireless, mobility, and RFID technologies.
Del Mar Pharmaceuticals, Inc. (DMPI)
DelMar Pharmaceuticals, Inc. was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company’s lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. VAL-083 benefits from extensive clinical research sponsored by the US National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.
Digital Cinema Destinations Corporation (DCIN)
Digital Cinema Destinations Corp. is dedicated to transforming its movie theaters into interactive entertainment centers. The Company provides consumers with uniquely satisfying experiences, combining state-of-the-art digital technology with engaging, dynamic content that far transcends traditional cinematic fare. The Company's customers enjoy live and pre-recorded alternative programming such as concerts, operas, ballets, sporting events, conferences, interactive videogames, auctions, fashion shows and, on an ongoing basis, the very best major motion pictures. As of April 1, 2013, Digiplex operates 18 cinemas and 178 screens in AZ, CA, CT, NJ, OH and PA. You can connect with Digiplex via Facebook, Twitter, YouTube and Blogger. Digiplex is also participating in DigiNext, a unique, specialty content joint venture (with Nehst Studios) featuring curated content from festivals around the world. DigiNext releases typically include innovative live Q&A sessions between the audience and cast members.
Direct Insite Corp (DIRI)
Direct Insite Corp. delivers cloud-based e-invoicing solutions for AP, AR and payments automation. For nine years, Direct Insite has built a track record in automating some of the most demanding financial environments, including the shared services centers for Fortune 3000 companies. Today, over 300,000 suppliers and customers use our e-invoicing network across 100 countries (representing more than 35 currencies and 17 languages). Direct Insite’s Invoices On-Line (IOL) suite simplifies AP and AR processes such as: electronic invoice distribution and submission; purchase order submission, distribution and acknowledgement, invoice processing and validation, line-item matching, approval routing, invoice consolidation, dispute management, e-payment processing, and reporting and analysis.
Document Security Systems, Inc. (DSS)
DSS, a leader in anti-counterfeit, authentication, and mass–serialization technologies, provides turnkey security solutions to corporations, governments, and financial institutions around the world. Our custom security programs are designed to protect against product diversion, counterfeit, theft, and other costly and damaging occurrences. From risk analysis and vulnerability assessment, to systems integration and monitoring, DSS offers the advanced tools and knowledge base needed to protect the world’s most valuable and at-risk brands.
DS Healthcare Group, Inc. (DSKX)
DS Healthcare Group, Inc., formerly Divine Skin Inc., is the fastest growing biotech company in the hair loss industry. The Company pioneered the use of solid lipid nanosomes for dermal delivery of chemicals, which improves efficacy and reduces skin irritation. Its two flagship products, Spectral.DNC, a topical hair regrowth treatment, and Revita, a hair regrowth shampoo, are the most advanced therapies on the market that target multiple etiologies behind hair loss. DS Healthcare’s product portfolio includes innovative solutions for hair loss, skincare, and personal care needs. The company formulates, markets, and sells its products through its worldwide distribution network of specialty retailers, spas, salons, and other distributors.
DURECT Corporation (DRRX)
DURECT is a specialty pharmaceutical company developing innovative drugs for pain and chronic diseases, with late-stage development programs including REMOXY®, POSIDUR™, ELADUR®, and TRANSDUR®-Sufentanil. DURECT’s proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs.
Elephant Talk Communications Corp. (ETAK)
Elephant Talk Communications Corp. is a leading international provider of mobile proprietary Software Defined Network Architecture (Software DNATM) platforms for the telecommunications industry that empower Mobile Network Operators (MNOs) and Mobile Virtual Network Operators (MVNOs), Enablers (MVNEs) and Aggregators (MVNAs) with a full suite of applications, Full OSS/BSS Systems, Delivery Platforms, Support and Managed Services, on-site, cloud, hybrid and S/PaaS solutions, including Network, Mobile Internet ID Solutions, Secure Remote Access Management, Loyalty Management and Transaction Processing Services, superior Industry Expertise and high quality Customer Service without substantial upfront investment. Elephant Talk counts several of the world's leading Mobile Operators amongst its customers including Vodafone, T-Mobile and Zain, and virtually all business is focused on tier 1 and tier 2 operators worldwide.
Envision Solar International, Inc. (EVSI)
Headquartered in San Diego, California, Envision Solar designs and markets patented Solar Tree® products that transform parking lots into differentiated, renewable generation plants. The Company sets itself apart from the market with its unique offering of advanced, high quality solar with beautiful and iconic design. The Solar Tree® structure works as a billboard for a company’s green credentials while producing clean energy and improving the aesthetics of any parking lot. Envision Solar is the recipient of numerous awards for its Solar Tree® structure, with it becoming the world’s most recognized image for solar shade structures. Envision Solar knows that for businesses today making a green statement to customers and employees is incredibly important and the Company offers the tools to make that statement visible and also beautiful.
Fusion Telecommunications International, Inc. (FSNN)
Fusion is a leading provider of cloud communications, cloud computing and managed applications solutions to small, medium and large businesses, and carriers worldwide. Fusion’s advanced, high availability service platform enables the integration of leading edge products and services in the cloud, including hosted voice, data, managed network services, storage, security, data center services and disaster recovery. Fusion’s innovative yet proven cloud-based solutions lower our customers’ cost of ownership, and deliver new levels of security, flexibility, scalability and speed of deployment.
Galaxy Gaming, Inc. (GLXZ)
Galaxy Gaming, Inc., is an established international gaming company specializing in the development, acquisition and manufacturing of proprietary casino table games and enhanced electronic wagering platforms. Casinos use our products in lieu of public domain games (blackjack, craps, roulette) because of the popularity among players and higher profit margins. Headquartered in Las Vegas, in business since 2006, we have organically grown to become the second largest company producing and distributing casino table games in the world. Notable blackjack side bets include Lucky Ladies and 21+3. Popular premium games include Emperor’s Challenge Pai Gow and High Card Flush, which was voted Casino Journal’s Best New Table Game for 2012.
Galena Biopharma, Inc. (GALE)
Galena Biopharma, Inc. is a Portland, Oregon-based biopharmaceutical company that develops innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care.
Galena's lead product is NeuVax™. NeuVax™ (nelipepimut-S) is the immmunodominant nonapeptide derived from the extracellular domain of the HER2 protein, a well-established target for therapeutic intervention in breast carcinoma. The nelipepimut sequence stimulates specific CD8+ cytotoxic T lymphocytes (CTL) following binding to HLA-A2/A3 molecules on antigen presenting cells (APC). These activated specific CTLs recognize, neutralize and destroy through cell lysis HER2 expressing cancer cells, including occult cancer cells and micrometastatic foci. The nelipepimut immune response can also generate CTLs to other immunogenic peptides through inter- and intra-antigenic epitope spreading. Based on a successful Phase 2 trial, which achieved its primary endpoint of disease-free survival (DFS), the Food and Drug Administration (FDA) granted NeuVax a Special Protocol Assessment (SPA) for its Phase 3 PRESENT (P revention of Recurrence inEarly-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) study. The Phase 3 trial is ongoing and additional information on the study can be found at the recently updated website www.neuvax.com.
According to the National Cancer Institute, over 230,000 women in the U.S. are diagnosed with breast cancer annually. Of these women, only about 25% are HER2 positive (IHC 3+). NeuVax targets approximately 50-60% of HER2-negative patients (IHC 1+/2+ or FISH < 2.2) who achieve remission with current standard of care, but have no available HER2-targeted adjuvant treatment options to maintain their disease-free status.
Glyeco, Inc. (GLYE)
GlyEco, Inc. is a green chemistry company which transforms used glycols, a hazardous waste, into profitable green products. The Company's patent-pending technology recycles polluted glycols to a purity level equal to refinery produced material. This unique process cleans all five types of polluted glycols: HVAC, Textiles, Automotive, Airline and Medical. World-wide consumption for refinery produced ethylene glycol is over 5 Billion gallons per year.
GreenHunter Energy, Inc. (GRH)
GreenHunter Energy, Inc., through its subsidiaries, provides total water management solutions for shale or ‘unconventional’ oil and gas exploration in the Marcellus, Eagle Ford, and Bakken shale plays in the United States. It develops and manages salt water disposal wells, customized water purification facilities, comprehensive fluid tracking systems, modular water tank storage, trucking, and rail and barge modes of fluid transfer. The company intends to provide water disposal, water recycling, logistics and hauling services, and equipment rentals to oilfield operators; and oilfield water treatment service under the Frac-Cycle name. It also provides RAMCAT (Remote Access Management Compliance Asset Tracking), a well-head management system and compliance tool to provide a method for remote activity observation via a Web-based portal for management of well-head fluids; and equipment and tanks for rental. GreenHunter Energy, Inc. was incorporated in 2005 and is headquartered in Grapevine, Texas.
GSE Systems, Inc. (GVP)
GSE Systems, Inc. is a world leader in real-time, high-fidelity simulation, training and engineering solutions to the energy industry. With over 40 years of experience, GSE’s tailored comprehensive and modular solutions help customers achieve performance excellence in design, training, and operations.
The Hackett Group (HCKT)
The Hackett Group, a global strategic business advisory and operations improvement consulting firm, is a leader in best practice advisory, business benchmarking, and transformation consulting services including strategy and operations, working capital management, and globalization advice. Utilizing best practices and implementation insights from more than 7,500 benchmarking studies, executives use The Hackett Group's empirically-based approach to quickly define and implement initiatives that enable world-class performance. Through its REL group, The Hackett Group offers working capital solutions focused on delivering significant cash flow improvements. Through its Archstone Consulting group, The Hackett Group offers Strategy & Operations consulting services in the Consumer and Industrial Products, Pharmaceutical, Manufacturing, and Financial Services industry sectors. Through its Hackett Technology Solutions group, The Hackett Group offers business application consulting services that help maximize returns on IT investments. The Hackett Group has completed benchmark studies with over 2,800 major corporations and government agencies, including 97% of the Dow Jones Industrials, 86% of the Fortune 100, 90% of the DAX 30 and 48% of the FTSE 100.
Health Revenue Assurance Holdings, Inc. (HRAA)
HRAA is a leading provider of revenue integrity technology and services for healthcare organizations across the US, interpreting data to ensure that healthcare is efficient and effective for everyone. Founded in 2001 and based out of Plantation, FL, HRAA combines years of industry expertise with best-in-breed technology to create market leading business intelligence products and consulting services to improve the healthcare delivery experience for doctors, nurses and patients. HRAA offers the only full suite of solutions needed to keep up with the ever-changing healthcare industry, which include: data analytics software, business intelligence technology, medical coding, auditing, education, revenue cycle consulting, and ICD-10 transition solutions.
Hennessy Advisors, Inc. (HNNA)
Hennessy Advisors, Inc. is the publicly traded investment manager of the Hennessy Funds. Hennessy offers a broad range of domestic equity, sector and specialty, balanced and fixed income products. The firm is committed to its consistent and repeatable investment process, combining time-tested stock selection strategies with a highly disciplined, team-managed approach. Our business strategy is to grow our mutual fund assets under management through two distinct efforts: marketing and sales efforts and strategic purchase of management related assets.
The firm was founded in 1989 as a broker dealer, primarily serving individual investors. In 1996, Hennessy launched its first mutual fund, the Hennessy Balanced Fund, and in 2000 made its first acquisition, the Cornerstone Growth and Cornerstone Value Funds. Hennessy became a public company in 2002 following its initial public offering, while managing $350 million in assets. In the ensuing years, Hennessy Advisors has made six additional acquisitions, encompassing 20 mutual funds, several of which were merged into existing Hennessy Funds. Today Hennessy Advisors manages 16 mutual funds, with over $3.2 billion in assets under management.
The company serves clients with integrity, honesty and candor. Hennessy Advisors' strength lies in its consistent investment style and commitment to managing their mutual funds for the benefit of their shareholders. Our firm was founded on these principles, and the same principles guide us today. Our goal is to provide investment products that shareholders can have confidence in, knowing their money is invested as promised and managed in their best interest.
Heska Corporation (HSKA)
Heska Corporation develops, manufactures, markets, sells, and supports veterinary products for canine and feline companion animal health markets in the United States and internationally. The company offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HEMATRUE veterinary hematology analyzer to measure white and red blood cell count, platelet count, and hemoglobin levels in animals; VitalPath blood gas and electrolyte analyzer to measure blood gases, electrolytes, hematocrit, and other parameters; and IV pumps, as well as services and supports HESKA CBC-DIFF veterinary hematology system. It also provides point-of-care diagnostic test products comprising heartworm diagnostic products for dogs and cats; veterinary diagnostic laboratory products and services, such as allergy diagnostic products and services; pharmaceuticals and supplements, including heartworm prevention and hypothyroid treatment products, and nutritional supplements; vaccines and other biologicals for allergy treatment and feline respiratory diseases; and veterinary imaging instruments and services, such as digital radiography solutions and ultrasound systems, as well as sells mobile digital radiography products consumable supplies. In addition, the company offers bovine vaccines; biological and pharmaceutical products for other animal health companies; and various turnkey services comprising research, licensing, production, labeling, and packaging, as well as provides validation support and distribution services. Heska Corporation sells its products to veterinarians through a field organization, a telephone sales force, and independent third-party distributors, as well as trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. Heska Corporation was founded in 1988 and is headquartered in Loveland, Colorado.
ImmunoCellular Therapeutics, Ltd. (IMUC)
ImmunoCellular Therapeutics, Ltd. (IMUC) is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular is conducting a phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellular's pipeline also includes ICT-121, a dendritic cell vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells.
Innovative Food Holdings Inc. (IVFH)
Innovative Food Holdings, through its subsidiaries, is a leading nationwide provider of direct from source specialty foods, healthcare foods, gluten free foods, and artisanal and local foods, to the professional foodservice market. IVFH also markets those products directly to the consumer, through its website at www.forthegourmet.com. Many of Innovative Food Holdings' 7,000+ products are used on a daily basis by approximately 30,000 of some of the leading professional chefs across the United States.
International Stem Cell Corporation (ISCO)
International Stem Cell Corporation is a California-based, publicly traded biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) to treat diseases of the brain, liver and the eye. ISCO’s core technology, parthenogenesis, creates pluripotent human stem cells from unfertilized oocytes (eggs) avoiding ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals with minimal immune rejection after transplantation. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com).
Keating Capital, Inc. (KIPO)
Keating Capital is a publicly traded business development company that specializes in making pre-IPO investments in innovative, emerging growth companies that are committed to and capable of becoming public. We provide investors with the ability to participate in a unique fund that allows our stockholders to share in the potential value accretion that we believe typically occurs once a company transforms from private to public status.
Kenactiv Innovations, Inc. (OPHI)
Kenactiv Innovations is maximizing the ability of business and industry to benefit from the renewability of kenaf, and other natural fibers, and to harness their power to improve many of the products and processes on which the world relies. Our innovative approach to crop management, processing, product design, and high volume manufacturing allows modern manufacturers to reap the benefits of highly renewable, high performance natural fiber materials without compromise. Our products and solutions replace petroleum-based synthetic and less sustainable natural alternatives, and offer significant performance benefits including lightweight strength, insulation, absorbency, and thermal tolerance. They make products and processes better, more cost effective, and reduce their impact on the environment. They also provide improved supply chain stability, reduced levels of waste and toxins from manufacturing processes, conservation of limited natural resources, reduced risk, and a safer work environment.
Lattice Incorporated (LTTC)
Lattice Incorporated (“Lattice” or the “Company”), founded in 1973, provides secure communications and information technology, specializing in deploying advanced technology and services to create innovative, cost-effective solutions for the Company’s global customers.
The Company provides both wholesale and direct services to correctional facilities and their service providers in the U.S., Canada and Europe. Expansion of Lattice’s direct and wholesale services, including increased technology equipment and software sales to wholesale customers, is expected to drive revenue growth and increased margins in the quarters ahead.
LCA-Vision Inc. (LCAV)
LCA-Vision Inc., a leading provider of laser vision correction services under the LasikPlus® brand, operates 53 LasikPlus® vision centers in the United States: 49 full-service LasikPlus® fixed-site laser vision correction centers and four pre- and post-operative LasikPlus® satellite centers. LCA-Vision’s LasikPlus® laser vision correction centers are staffed with skilled ophthalmologists and other healthcare professionals. LCA-Vision uses sophisticated diagnostic equipment and advanced laser technologies to help correct nearsightedness, farsightedness and astigmatism. In business for more than 16 years, LCA-Vision has performed more than 1.2 million procedures since FDA approval of photorefractive keratectomy (PRK) in late 1995.
LeMaitre Vascular (LMAT)
LeMaitre Vascular is a provider of devices and implants for the treatment of peripheral vascular disease, a condition that affects more than 20 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of the vascular surgeon.
Lightbridge Corporation (LTBR)
Lightbridge Corporation is developing and commercializing next generation nuclear fuel technology that will increase the power output of existing and new reactors, reduce nuclear waste and enhance proliferation resistance. The Company also is a leading provider of nuclear energy advisory services to commercial and governmental entities worldwide. Lightbridge is well positioned to serve the growing market opportunity for next generation nuclear fuel. Global nuclear power generation is projected to increase by more than 73% by 2035. Worldwide, 437 reactors are in operation today, and 71 reactors are under construction, including 29 in China and 7 in India.
Max Sound, Corporation (MAXD)
Max Sound is the creator of the audio process that brings high definition (HD) sound to digital media. MAX-D is to audio what HD is to video. MAX-D is the technology that dramatically improves sound quality by restoring the lost, compressed sound harmonics, while preserving the smallest possible file size. MAX-D HD is hardware/platform agnostic – no need to change equipment or infrastructure. With 23 patents pending, MAX-D makes any system sound better. The first two vertical markets being addressed with the Company’s three-pronged ‘Go To Market’ strategy are Music and Mobile. Recent milestones include (a) Qualcomm partnership to develop MAX-D HD on the Snapdragon smartphone chip; (b) completed acquisition of Liquid Spins and subsequent partnership with InComm (billion dollar industry leader of prepaid cards) for prepaid music gift cards and white label program for retailers, (c) signed internationally popular music artist Pitbull as brand ambassador.
Medifocus, Inc. (MFS)
Medifocus develops and commercializes minimally invasive focused heat systems for the treatment of cancerous and benign tumors, and enlarged prostate, medically known as Benign Prostatic Hyperplasia ("BPH"). With the recent acquisition of Prolieve®, Medifocus now owns a revenue generating commercial BPH treatment product targeting the $8 billion BPH drug therapy market and generating cash flow to support the development and commercialization of other catheter based or Adaptive Phased Array (APA) based focused heat systems for targeted thermotherapy of surface, subsurface and deep seated localized and regional cancers. The Company owns two technology platforms with comprehensive US and international patent protection: 1: The Endo-thermotherapy Platform-from which Prolieve was developed can potentially used to treat cancers in prostate, rectal, cervical and esophageal, and 2: The Adaptive Phased Array (APA) Microwave Focusing Platform-invented by MIT, licensed to Medifocus, directs precisely focused microwave energy at tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. The Company's APA 1000 Breast Cancer Treatment System, developed from the APA technology platform, is currently in pivotal Phase-III clinical trials. Please visit www.medifocusinc.com and www.prolieve.com for more details.
MGT Capital Investments, Inc. (MGT)
MGT and its subsidiaries are engaged in the business of acquiring, developing and monetizing intellectual property rights. MGT Gaming, Inc., a majority-owned subsidiary, owns U. S. Patent No. 7,892,088 relating to casino gaming systems. In November 2012, MGT Gaming filed a patent infringement suit against Caesars Entertainment Corporation, MGM Resorts International, Inc., WMS Gaming - a subsidiary of WMS Industries, Inc., Penn National Gaming, Inc., and Aruze Gaming America, Inc.
In addition, the Company owns Medicsight, Inc., a medical technology company with patent ownership and operations in imaging software and hardware devices. Medicsight's computer-aided detection software assists radiologists with detection of colorectal polyps, and has received regulatory approvals including CE Mark and U. S. FDA clearance.
MVC Capita, Inc. l (MVC)
MVC Capital is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company under the 1940 Act. MVC provides debt and equity investment capital to fund growth, acquisitions and recapitalizations of small and middle-market companies in a variety of industries primarily located in the United States. MVC’s investments can take the form of common and preferred stock and warrants or rights to acquire equity interests, senior and subordinated loans, or convertible securities. MVC’s common stock is traded on the New York Stock Exchange ("NYSE") under the symbol "MVC."
Naked Brand Group, Inc. (NAKD)
Naked is one of the world’s most luxurious and environmentally conscious underwear brands. Naked’s products are constructed from only the finest fabrics. Each smooth and light-weight garment seamlessly forms to your body making you feel like you’re wearing nothing at all. Naked underwear and undershirts are sold in high-end boutiques and department stores throughout North America including Nordstrom, Holt Renfrew, Boys’co, Kitson, Akira and Freshpair.com. A donation from every purchase helps to support Project World Citizen, a charity driven to empower and educate the children of Ghana.
NanoViricides, Inc. (NNVC)
NanoViricides, Inc., in a pre-clinical biotech company developing anti-viral drugs to destroy a wide range of viruses in and on the body as well as in the eye. The Company has developed a platform technology, based on the principles of nanotechnology, that enables rapid drug development either in the lab or in the field.
The Company has successfully treated 5000 animals after infection with a wide range of viral diseases. These include all forms of influenza, HIV/AIDS, herpes of the genitals and the eye, adenovirus of the eye, dengue and dengue hemorrhagic fever, rabies and Ebola.
Construction of a new facility and pilot production plant is currently underway and human trials for our influenza cure are now planned for the second half of 2014.
The Company is well funded and currently actively trades on the OTCBB with a market cap of $120M.
NeoStem, Inc. (NBS)
“NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy market. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.
Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem's most clinically advanced therapeutic, AMR-001, is being developed at Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. Athelos Corporation ("Athelos"), which is approximately 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSELTM Technology platform as well as our mesenchymal stem cell product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert, giving us a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a substantial intellectual property estate, we believe we are well positioned to succeed.”
NetDimensions Holdings Ltd. (NETDY)
Established in 1999, NetDimensions is a global provider of performance, knowledge and learning management systems.
NetDimensions provides companies, government agencies and other organizations with talent management solutions to personalize learning, share knowledge, enhance performance, foster collaboration, and manage compliance for employees, customers, partners and suppliers.
Through the company’s own offices worldwide, as well as through a global reseller network that extends to over 40 countries, NetDimensions serves over 380 clients with more than 2.8 million active users.
Recognized as one of the talent management industry's top-rated technology suppliers in overall customer satisfaction, NetDimensions has been chosen by leading organizations worldwide. NetDimensions’ global solutions help these organizations achieve productivity & efficiency improvements, cost reduction, risk management, and cultural & process innovation. NetDimensions is ISO 9001 certified and NetDimensions hosted services are ISO 27001 certified.
New Western Energy Corp. (NWTR)
New Western Energy Corp. is an independent energy company engaged in the acquisition, development, production, and exploration of oil, gas and minerals primarily in North America.
Northwest Biotherapeutics, Inc. (NWBO)
Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the U.S. and Europe. The Company has a broad platform technology for DCVax dendritic cell-based vaccines. The Company’s lead program is a 312-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal brain cancer. The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I/II trials in multiple other cancers. The Company has also conducted a Phase I/II trial with DCVax for metastatic ovarian cancer together with the University of Pennsylvania.
NTS Communications, Inc. (NTS)
NTS Communications is a provider of high speed broadband services, including internet access, digital cable TV programming and local and long distance telephone service to residential and business customers in northern Texas and southeastern Louisiana. NTS' Fiber-To-The-Premise (FTTP) network provides one of the fastest internet connections available.
Oculus Innovative Sciences, Inc. (OCLS)
Oculus Innovative Sciences, Inc. is a commercial healthcare company that designs, produces and markets innovative, safe and effective drugs, devices and nutritional products. Oculus is pioneering innovative solutions in multiple markets for the dermatology, surgical, wound care and animal healthcare markets, and has commercialized products in the United States, Europe, India, China, Mexico and select Middle East countries. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America.
OHR Pharmaceutical Inc. (OHRP)
OHR Pharmaceutical Inc. is a pharmaceutical company dedicated to the clinical development of new drugs for underserved therapeutic needs in large and growing markets. The Company is focused on advancing its pipeline products currently in phase II clinical development: Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration, and OHR/AVR118 for the treatment of cancer cachexia.
OncoSec Medical Incorporated (ONCS)
OncoSec Medical Incorporated is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers.
ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives.
OncoSec's core technology is based upon its proprietary use of an electroporation platform to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials.
OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers.
Orient Paper, Inc. (ONP)
Orient Paper, Inc. (“Orient Paper”) is a leading paper manufacturer in North China. Using recycled paper as its primary raw material, Orient Paper produces and distributes three types of paper products namely, packaging paper (corrugating medium paper), offset printing paper, and other paper products, including digital photo paper, and household/tissue paper that the company is currently expanding into.
With production operations based in Baoding in North China’s Hebei Province, Orient Paper is located strategically close to the Beijing and Tianjin region, home to a growing base of industrial and manufacturing activities and one of the largest markets for paper products consumption in the country.
Orient Paper’s production facilities are controlled and operated by its wholly owned subsidiary Shengde Holdings, Inc., which in turn controls and operates Baoding Shengde Paper Co., Ltd., and Hebei Baoding Orient Paper Milling Co., Ltd for manufacturing digital photo, printing and packaging paper.
Founded in 1996, ONP has been listed on the NYSE MKT Board since December 2009.
OTC Markets Group, Inc. (OTCM)
OTC Markets Group Inc. operates Open, Transparent and Connected financial marketplaces for 10,000 U.S. and global securities. Through our OTC Link® ATS, we directly link a diverse network of broker-dealers that provide liquidity and execution services for a wide spectrum of securities. We organize these securities into marketplaces to better inform investors of opportunities and risks – OTCQX®, The Best Marketplace with Qualified Companies; OTCQB®, The Venture Stage Marketplace with U.S. Reporting Companies; and OTC Pink®, The Open Marketplace with Variable Reporting Companies. Our data-driven platform enables investors to easily trade through the broker of their choice at the best possible price and empowers a broad range of companies to improve the quality and availability of information for their investors. To learn more about how we create better informed and more efficient financial marketplaces.OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS.
PAR Technology Corp (PAR)
PAR Technology Corporation's stock is traded on the New York Stock Exchange under the symbol PAR. PAR’s Hospitality segment has been a leading provider of restaurant and retail technology for more than 30 years. PAR offers technology solutions for the full spectrum of restaurant operations, from large chain and independent table service restaurants to international quick service chains. PAR’s Hospitality business also provides hotel management systems with a complete suite of powerful tools for guest management, recreation management, and timeshare/condo management. In addition, PAR offers the spa industry a leading management application specifically designed to support the unique needs of the resort spa and day spa markets, a rapidly growing hospitality segment. Products from PAR also can be found in retailers, cinemas, cruise lines, stadiums and food service companies. PAR’s Government Business is a leader in providing computer-based system design, engineering and technical services to the Department of Defense and various federal agencies.
Pharmagen, Inc. (PHRX)
With a multifaceted approach, Pharmagen, Inc. is meeting the demands of the health provider market through dynamic, independent wholesale, compounding/admix, and innovative IT solutions. Nationally focused, we are a distributor of specialty drugs, compounding and admix pharmacy, and a producer of over-the-counter (OTC) branded multivitamins. The Food and Drug Administration continues to see an increasing number of shortages, especially those involving sterile injectable drugs. We currently function as a total solution provider to hospitals, offering both sterile compounding/admix pharmacy and a just-in-time supply of products that are hard to find due to drug manufacturers’ production shortages. Leveraging our understanding of drug shortages, our long term goal is to become an FDA approved manufacturer of habitually short supply, sterile pharmaceuticals. Through an industry changing, cGMP + ® process, employing single-use, modular systems, we intend to be the gold standard of sterile production in the United States.
In addition to pharmaceuticals, we manufacture and distribute over-the-counter (OTC) branded health supplements. Our innovative approach to OTC is to create suites of products designed to work in conjunction with prescription medications to alleviate side effects and/or prevent drug interactions. With an aging population, more Americans than ever rely on prescription medications, and dangerous drug interactions are a growing problem. We are currently analyzing several OTC products that would allow us to become a powerful player in the multi-billion-dollar health supplement market.
Pressure BioSciences, Inc. (PBIO)
We are a life sciences tools company focused on the development and sale of proprietary laboratory instrumentation and consumables based on our patented and enabling pressure cycling technology ("PCT"). PCT uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels (58,000 psi or greater) to safely, conveniently and reproducibly control the actions of molecules in biological samples, e.g., human, animal, plant, and microbial cells and tissues. Our current focus is on PCT-enhanced systems to address the challenging problems inherent in biological sample preparation, a crucial laboratory step performed by thousands of biological scientists worldwide. Through 2012, we have installed over 225 PCT Systems in leading academic, and biotech companies worldwide.
Prima BioMed Limited (PBMD)
Prima BioMed is a globally active biotechnology company. As a leader in personalized bio-therapeutic products for cancer, Prima is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and to maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell product currently in clinical trials for ovarian cancer patients who are in remission.
Professional Diversity Network LLC (IPDN)
Professional Diversity Network develops and operates online networks dedicated to serving diverse professionals in the United States and providing them with access to employment opportunities. Professional Diversity Network offers employers who value diversity an online platform in which to identify and acquire diverse talent for their hiring needs. Professional Diversity Network owns and operates professional networking communities including: www.iHispano.com for Hispanic Professionals, www.AMightyRiver.com for African American professionals, www.WomensCareerChannel.com for Female Professionals, www.Military2Career.com for Veterans, www.ProAble.com for Professionals with Disabilities, www.OutProNet.com for professionals in the Gay Community, and www.AsianCareerNetwork.com for Asian professionals.
Profire Energy, Inc. (PFIE)
Profire Energy is an oilfield-technology company, specializing in burner management systems. Our products monitor, manage, and reignite the burner-flames that are widely used in the oil/gas industry, ensuring reliable oilfield operations. By using Profire products,oil/gas companies become safer, more eco-friendly, and more efficient. Profire is a profitable and debt-free company, and was recognized in 2012 as one of the fastest-growing companies in the world by International Business Times.
Provectus Pharmaceuticals, Inc. (PVCT)
Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and metastatic cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis.
Pulse Seismic, Inc. (PSLDF)
Pulse Seismic Inc. ("Pulse") is a market leader in the acquisition, marketing and licensing of 2D and 3D seismic data to the western Canadian energy sector. Pulse owns the second-largest licensable seismic data library in Canada, currently consisting of approximately 28,300 square kilometres of 3D seismic and 340,000 kilometres of 2D seismic. The library extensively covers the Western Canada Sedimentary Basin where most of Canada’s oil and natural gas exploration and development occur. Pulse trades on the Toronto Stock Exchange under the symbol PSD and on the OTCQX under PLSDF.
PureSafe Water Systems, Inc. (PSWS)
PureSafe Water Systems, Inc. founded in 1987, was previously known as Water Chef, Inc. The Company was taken over by a new management team in 2007, at which time the name was changed.
PSWS has a unique patented mobile water filtration system (First Response Water System- FRWS) that was designed to be both an emergency response water filtration system, as well as, a permanent solution where drinkable water is not available. The self-contained and self-powered PureSafe System can be mobilized to a site and within 30 minutes will be producing drinking quality water from flood waters, surface and fresh water, desalinating ocean and/or brackish waters. This mid- range, 30,000 gallon per day system has also found a huge application in known contaminated water sources where water clarity, water borne disease and high bacteria content exist, and where mobile, self-contained systems are applicable to bring clean water to the population wherever they are located. The system can dispense water in bulk, by container or in half liter plastic bags to suit the situation.
The PSWS product is one of the most “versatile” mobile, self- contained systems available on the market due to its patented assemblage of multiple filtration technologies all with one system. This allows the patented FRWS to immediately begin desalinating salt water during a catastrophe, only to be deployed to a separate location within minutes to clean bacteria from a public water or fresh water source with no equipment changes needed.
Rexahn Pharmaceuticals, Inc. (RNN)
Rexahn Pharmaceuticals Inc. is a clinical stage biopharmaceutical company focused on developing best-in-class market leading therapeutics for the treatment of cancer. By targeting biological mechanisms which are highly specific to cancer cells, Rexahn has developed drug candidates that demonstrate increased efficacy and reduced toxicity, are efficacious against multiple drug resistant cancer cells and show synergism with existing cytotoxic compounds. The specific nature of these drug candidates also allows for the development of specific biomarkers to identify relevant patient populations for clinical trials and serve as surrogate markers for clinical efficacy. Rexahn currently has three compounds in clinical development: Archexin which has completed a Phase IIa clinical study in patients with advanced pancreatic cancer, RX-3117 (which is partnered with Teva Pharmaceuticals) is in Phase I and RX-5902 is in Phase I. Rexahn will be initiating four new clinical trials during 2013 and reporting on the completed clinical data from three of these trials by the end of 2014.
RiceBran Technologies (RIBT)
RiceBran Technologies is a human food ingredient and animal nutrition company focused on the procurement, bio-refining and marketing of numerous products derived from rice bran. Rice Bran Technologies has proprietary and patented intellectual property that allows us to convert rice bran, one of the world's most underutilized food sources, into a number of highly nutritious human food ingredient and animal nutrition products. Our target markets are human food ingredients and animal nutrition manufacturers and retailers, as well as natural food, functional food and nutraceutical supplement manufacturers and retailers, both domestically and internationally.
Rimrock Gold Corp. (RMRK)
Rimrock Gold is a diversified mineral exploration company focused on identifying, acquiring, advancing, and drilling high-grade gold-silver exploration projects in Nevada, and lithium exploration projects in Quebec. The company has a very capable management team, and is led by an experienced and successful board. The Company’s main exploration assets comprise a 100% interest in the Rimrock, West Silver Cloud, and Pony Spur gold-silver projects in Nevada. The company recently announced that it has purchased from Geologix Resources (GIX.TSX.V) the advanced stage exploration Silver Cloud epithermal bonanza gold-silver property in Nevada (“Silver Cloud Property”) totaling 4,467 hectares. In addition, the company owns the Abigail, Lac Kame and EM-1 lithium projects in the James Bay region of Quebec, Canada totaling 11,360 hectares.
RiT Technologies Ltd. (RITT)
RiT is a leading provider of IIM solutions and a developer of an innovative indoor optical wireless technology solution. Our IIM products provide and enhance security and network utilization for data centers, communication rooms and work space environments. They help companies plan and provision, monitor and troubleshoot their communications networks, maximizing utilization, reliability and physical security of the network while minimizing unplanned downtime. RiT’ IIM solutions are deployed around the world, in a broad range of organizations, including data centers in the private sector, government agencies, financial institutions, airport authorities, healthcare and education institutions. Our recently launched Beamcaster™ product, is the first of our indoor optical wireless technology solutions. It is designed to help customers streamline deployment, reduce infrastructure design, installation and maintenance complexity and enhance security in a cost effective way. RiT’s shares are traded on the NASDAQ Capital Market.
Rocky Mountain Chocolate Factory, Inc. (RMCF)
Rocky Mountain Chocolate Factory, Inc. (RMCF) incorporated in 1982 and is headquartered in Durango, Colorado. The Company is an international franchisor of gourmet chocolate and confection stores and manufacturer of an extensive line of premium chocolates and other confectionery products. The Company's revenues are derived from three principal sources: sales to franchisees and others of chocolates and other confectionery products manufactured by the Company; the collection of initial franchise fees and royalties from franchisees' sales; and sales at Company-owned stores of chocolates and other confectionery products.
The Company’s majority-owned subsidiary, U-Swirl, Inc. (SWRL), is a franchisor and operator of self-serve frozen yogurt stores. The Company, its subsidiary and its franchisees operates approximately 425 Rocky Mountain Chocolate Factory and U-Swirl self-serve frozen yogurt stores in 42 states, Canada, Japan and the United Arab Emirates.
Santeon Group, Inc. (SANT)
Santeon Group Inc. is a diversified software products and services company specializing in the transformation and optimization of business performance through the deployment of innovative products and services using Agile in and across the commercial, government and consumer sectors. Our innovative products and services enable organizations to optimize performance and maximize value. Our clients include state and local governments, federal agencies and numerous private sector customers. While our roots are in healthcare, our name means health, we have expanded into a more horizontal solution offering carrying the sameprincipals of building a “healthy” organization. Whether we are building solutions for commercial, government or consumers, the overall performance and health of the organization and how they benefit from our products and services is of the utmost importance.
SearchCore, Inc. (SRER)
Founded in 2010, SearchCore, Inc. is a diversified Internet marketing services company that specializes in connecting consumers with brands, products, and services. We do this by developing, operating, and monetizing vertical finder websites in business-to-business (B2B) and business-to-consumer (B2C) markets. SearchCore’s focus is on fragmented, disjoined niche markets that can benefit from its technology-based marketing services solutions and where it is positioned to build the #1 or #2 technology-based vertical finders website in a niche industry.
SearchCore combines its dynamic technology platform, highly experienced in-house sales and marketing team and significant Internet marketing services expertise to deliver effective marketing services solutions to its clients. SearchCore’s solutions save clients time and money and, just as importantly, deliver tangible and measurable results, including increased website traffic, greater in-store traffic and an enhanced business profile. Website visitors searching for the products and services provided by SearchCore’s clients enjoy an exceptional experience when visiting SearchCore’s finder sites. SearchCore’s clients pay a subscription-based monthly fee for inclusion on its finder sites plus additional fees for add-on and ancillary services. SearchCore is headquartered in Lake Forest, California.
SED International Holdings, Inc. (SED)
Founded in 1980, SED International Holdings, Inc. is a multinational, preferred distributor of leading computer technology, consumer electronics, small appliances, housewares, and personal care products. The company also offers custom-tailored supply chain management services ideally suited to meet the priorities and distribution requirements of the e-commerce, Business-to-Business and Business-to-Consumer markets. Headquartered near Atlanta, Georgia with business operations in California; Florida; Georgia; New Jersey; Texas; Bogota, Colombia and Buenos Aires, Argentina, SED serves a customer base of over 10,000 channel partners and retailers in the US and Latin America.
SG Blocks, Inc. (SGBX)
SG Blocks, Inc. is a publicly traded company listed on the OTC Bulletin Board under the symbol “SGBX”.
Since its inception in 2007, SG Blocks has been a leader in advancing and promoting the use of code-engineered cargo shipping containers for safe and “green” construction with innovative solutions. SG Blocks develops and implements technology that stands above other standardized container-construction while also being highly cost effective. Offering an exceptional product that exceeds many standard building code requirements, SG Blocks supports developers, architects, builders and owners in achieving greener construction, faster execution and stronger buildings of higher value.
Sirona Biochem Corp (SBM)
Sirona Biochem is a biotechnology company developing diabetes therapeutics, skin depigmenting and anti-aging agents for cosmetic use, biological ingredients and cancer vaccine antigens. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. Recent scientific studies have revealed that Sirona Biochem’s skin lightening agents are 14 and 7 times more effective than beta and alpha arbutin, two highly popular skin lightening agents. These agents are also shown to be safe in all of the standard safety tests. A recent study also showed that our diabetes compound, SBM-TFC-039, an SGLT2 inhibitor, reduced blood glucose more effectively than Johnson and Johnson’s SGLT2 inhibitor, canagliflozin. Sirona Biochem is the parent company of French-based biotechnology company, TFChem.
Single Touch Systems Inc. (SITO)
Single Touch Systems is an innovative mobile media technology developer that generates growing recurring revenue streams through its operating business while it pursues monetization of its intellectual property (IP) through its Single Touch Interactive R&D IP subsidiary. In its operating business the Company serves retailers, advertisers and brands with patented technologies to reach consumers via their wireless devices. Having sent out over 500,000,000 mobile messages to date, Single Touch generates recurring revenues by sending text messages to customers of a growing list of retailers including Walmart (NYSE:WMT), Hibbett Sports (NASDAQ:HIBB), and Hy-Vee, a top-20 supermarket chain. Through its IP business Single Touch has filed patent infringement suits and delivered Letters of Notification to some of the largest technology and media companies in the world and has the opportunity to generate additional licensing and patent settlement revenues.
SNAP Interactive, Inc. (STVI)
SNAP Interactive, Inc. develops, owns and operates online dating and social networking applications for social networking websites and mobile platforms. SNAP's flagship brand, AYI - AreYouInterested.com®, is one of the largest social dating applications on the Internet with over 60 million installs, and offers a completely integrated Facebook, iPhone, Android and Web application.
Stellar Biotechnologies, Inc. (KLH)
Stellar Biotechnologies, Inc. is a world leader in development, manufacture and commercialization of keyhole limpet hemocyanin (KLH). KLH is an important biomedical material that is derived only from a limited natural source.
Stellar Biotechnologies is uniquely positioned: Leading KLH products and practices amid rising demand for KLH from biopharmaceutical companies, clinicians and immunology researchers.
Stellar Biotechnologies is the only company dedicated solely to developing and commercializing KLH. The company applies leading aquaculture technology and experience aimed at ensuring sustainable supply, together with proprietary manufacturing methods, to deliver a range of high quality KLH products.
Stellar Biotechnologies’ core business is production of purified KLH for use in a new class of medicines known as therapeutic vaccines and in immunological research. Stellar is also developing KLH-based assays for use in immunodiagnostic applications.
The recent rising demand for KLH is driven by pharmaceutical and biotechnology companies developing innovative therapies that target the immune system such as KLH-conjugated vaccines for a wide variety of serious chronic diseases, and those that utilize KLH for drug screening and to assess immune response in clinical and preclinical settings. Stellar Biotechnologies’ revenues are derived primarily from the sale of its KLH products and services to companies such as these, and from the award of federal grants such as from the National Institutes of Health and the National Science Foundation.
Sutor Technology Group Limited (SUTR)
Sutor Technology Group is a leading China-based non-state-owned manufacturer and distributor of high-end fine finished steel products and welded steel pipes used by a variety of downstream applications. The Company utilizes a variety of in-house developed processes and technologies to convert steel manufactured by third parties into fine finished steel products, including hot-dip galvanized steel, pre-painted galvanized steel, acid-pickled steel, cold-rolled steel and welded steel pipe products. These products are used for household appliances, solar water heaters, automobiles, information technology, construction, and other applications. Currently Sutor has three major operating subsidiaries located in two provinces with 12 production lines capable of processing approximately 2 million metric tons of steel products annually.
Synthetic Biologics, Inc. (SYN)
Synthetic Biologics, Inc. is a biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases. The Company is developing an oral enzyme for the prevention of C. difficile infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and Acinetobacter infections. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis.
Sysorex Global Holdings Corp. (SYRX)
Sysorex Global Holdings Corp. is a leading provider of Information Technology Support Services for enterprise level IT environments including full life cycle software development, interface, integration, operational support, and IT Network Infrastructure Modernization Services. With over 30 years of operating history, they provide a wide range of consulting, systems engineering, cyber security, data analytics and program management expertise.
Targeted Medical Pharma (TRGM)
Targeted Medical Pharma is a Los Angeles-based biotechnology company that develops prescription medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company manufactures 10 proprietary prescription-only medical foods. These prescription medical foods and therapeutic systems are sold to physicians and pharmacies in the United States through the company’s subsidiary, Physician Therapeutics. These proprietary medications represent a novel approach to the management of certain disease states, focusing on safety and efficacy without the deleterious side effects of traditional, high dose prescription drugs. The company is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I.
The LGL Group, Inc. (LGL)
The LGL Group, Inc. is a globally-positioned producer of industrial and commercial products and services that is currently focused on the design and manufacture of highly engineered electronic components and subsystems. For over 90 years, LGL has been creating value for its shareholders by providing customers with products and services that reflect the Company’s commitment to operational excellence and technical innovation, and by disciplined deployment of capital resources.
ThermoEnergy Corporation (TMEN)
Founded in 1988, ThermoEnergy is a diversified technologies company engaged in the worldwide development, sales and commercialization of patented and/or proprietary wastewater treatment systems and clean combustion technologies. The company has spent nearly two decades developing sustainable water and wastewater recovery systems that help companies operate more efficiently, recover valuable resources, reduce their carbon footprints, and meet sustainability goals.
ThermoEnergy’s FracGen™ system provides an economical and effective solution to recover useable water from local aquifers, saving huge dollars that would have to be spent on purchasing and trucking in fresh water from distant locations. ThermoEnergy’s TurboFrac™ system is a cost effective solution to recover contaminated produced water and flow-back water created by the hydraulic fracturing of oil and gas wells, and recycle it into clean, usable water. In addition to recovering usable water for reuse in fracking operations, the TurboFrac system can concentrate the chemicals and other impurities for recycling or safe, cost-efficient disposal.
Towerstream Corporation (TWER)
Towerstream is a leading 4G and Small Cell Rooftop Tower company. The company owns, operates, and leases Wi-Fi and Small Cell rooftop tower locations to cellular phone operators, tower, Internet and cable companies and hosts a variety of customers on its network. Towerstream was originally founded in 2000 to deliver fixed-wireless high-speed Internet access to businesses and to date offers broadband services in over 13 urban markets including New York City, Boston, Los Angeles, Chicago, Philadelphia, the San Francisco Bay area, Miami, Seattle, Dallas-Fort Worth, Houston, Nashville, Las Vegas-Reno, and the greater Providence area.
TranSwitch Corporation (TXCC)
TranSwitch Corporation provides innovative integrated circuit (IC) and intellectual property (IP) solutions that deliver core functionality for video, voice, and data communications equipment for the customer premises and network infrastructure markets. For the customer-premises market, we offer multi-standard, high-speed interconnect solutions enabling the distribution and presentation of high-definition (HD) video and data content for consumer electronics applications. We also provide a family of best-in-class communications processors. For the network infrastructure market we provide integrated multi-core network processor System-on-a-Chip (SoC) solutions for Fixed, 3G and 4G Mobile, VoIP and Multimedia applications. TranSwitch’s customers are leading consumer electronics and telecom equipment companies around the globe.
Trio Resources, Inc. (TRII)
Trio Resources, Inc. is an exploration and small-scale processing company which plans to focus on the exploration and milling of mineralized materials located in historically prolific regions. Trio is organized to hold assets in the mining industry, targeting older mining camps with residual value. Trio’s intention is to conduct an exploration program, in conjunction with milling initiatives to monetize its existing above-ground mineralized material on-site, with the purpose of being cash-flow positive primarily through milling and marketing mineralized material and concentrate to refiners.
Unilife Corporation (UNIS)
Unilife is a U.S. based company engaged in the design, development, production and supply of injectable drug delivery systems. We build long-term collaborations with pharmaceutical and biotechnology companies seeking to utilize our innovative and highly differentiated devices to enable or enhance the clinical development, regulatory approval and lifecycle management of their injectable therapies. Our broad portfolio of platform-based device technologies includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, bolus injection devices and targeted delivery systems. Each of our proprietary device platforms can be customized to address specific customer, therapy and patient requirements.
Universal Business Payment Solutions Acquisition Corp (UBPS)
Universal Business Payment Solutions (UBPS) "launched" our future with the December 2012 acquisition of JetPay, a new breed acquirer and processor with major emphasis on mobile and cloud solutions, and A D Computer, a comprehensive payroll and tax service company, and laid the foundation for rapid expansion, the introduction of innovative, value-add solutions, and follow-on acquisitions.
UBPS, now doing business as JetPay Corporation, is focused on creating one-stop-shop payment solutions for small businesses, their employers and their customers. There are over 26 million small businesses nationwide. These businesses need payroll and tax services; merchant accounts; POS systems; and front and back-end card processing for their customers. Their employees increasingly need direct-to-card deposit products to access funds and make transactions - including the 60+ million un-and under-banked adults in the U.S. Our strategy is to drive growth by delivering a comprehensive and convenient payment infrastructure to existing and new customers. Second, our management team intends to incorporate emerging technologies, such as mobile and cloud, into new and value-add payment products and applications. Third, management has a superior platform from which to plan follow-on acquisitions to consolidate our presence in the fragmented payments industry in order to leverage the benefits of our innovations and achieve attractive economies of scale. We believe the implementation of this business strategy will enable us to achieve rapid growth and provide superior returns to our shareholders.
USA Technologies, Inc. (USAT)
USA Technologies provides end-to-end electronic payment solutions for the small-ticket, unattended retail market—a traditionally cash-only market sector that continues to transition to cashless payments. USA Technologies has led the unattended market’s transition to cashless by creating a turnkey service—ePort Connect®—that makes the transition to cashless seamless for customers requiring one-stop-shopping and value-add services that help improve their businesses. Cashless adoption, while still in its early stages, has fueled growth in USA Technologies’ customers and connections of 74% and 43% over the last three years, driving recurring revenue growth of 42% for its latest fiscal year ended June 30, 2012.
Vapor Corp (VPCO)
Vapor Corp. is a leading supplier of electronic cigarettes with a diverse product portfolio that includes the most recognized brands by both retailers and consumers in the industry. Vapor Corp. is also one of the only fully reporting, publicly traded electronic cigarette company in the United States.
Vasomedical, Inc. (VASO)
Vasomedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company’s main proprietary products are EECP® Therapy systems, the gold standard of ECP treatment. The Company operates through three wholly owned subsidiaries: VasoSolutions, Vasomedical Global and VasoHealthcare. VasoSolutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems, and other medical equipment operations; Vasomedical Global operates the Company’s China-based subsidiaries; and VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments.
Verastem, Inc. (VSTM)
Verastem, Inc. is discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells (CSCs) along with proprietary companion diagnostics. Verastem is developing therapies for the treatment of solid tumors including breast, ovarian, mesothelioma and other cancers. Verastem’s product candidates include inhibitors of focal adhesion kinase (FAK) and a dual inhibitor of PI3K/mTOR. VS-6063 is a FAK inhibitor that has completed Phase 1 and is currently in a Phase 1/1b clinical trial in combination with paclitaxel for patients with ovarian cancer. VS-6063 is planned to enter a potentially pivotal trial in mesothelioma midyear 2013. VS-4718 is a FAK inhibitor in IND-enabling toxicology studies that is anticipated to enter a Phase trial in advanced cancers during H1 2013. VS-5584 is a dual PI3K/mTOR inhibitor currently in IND-enabling toxicology studies to support initiation of a Phase 1 trial in advanced cancers H2 2013. These product candidates target the CSCs that have been implicated in aggressive cancers, metastasis, and chemotherapeutic resistance.
Verenium Corporation (VRNM)
Verenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes. Verenium’s tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.
VolitionRx Limited (VNRX)
VolitionRx is a life sciences company whose goal is to make its non-invasive blood tests for cancer as common and simple to use as existing diabetic and cholesterol tests on similar formats.
VolitionRx’s development activities are currently centered in Belgium with a focus on bringing its revolutionary diagnostic products to market first in Europe, then the U.S. and worldwide.
WaveFront Technology Solutions, Inc. (WFTSF)
Wavefront is a technology-based company with a reputation among its clients for quality, innovation and creativity. Focused on global markets, Wavefront utilizes its patented technology to provide meaningful economic results when exploration and production companies are faced with the challenges of optimizing oil production, well intervention and performance drilling.
Wavefront’s strategic value proposition is underpinned with 20 granted and 29 patents pending based on differentiated fluid flow technology. Marketed under the brand names, “Powerwave” and “Primawave”, the injection methodologies improve distribution of liquids in the ground.
Powerwave has been proven to be an effective method of: achieving mature field revitalization, increasing well productivity following well stimulation, and improving the rate of penetration of drilling extended reach wells. Primawave has been shown to substantially improve the distribution of fluids in the subsurface to effectively treat contaminants and has been verified as an environmental remedial strategy by Environment and Industry Canada.
With the evolution of our core “pressure-pulse technology” to encompass a portfolio of products, Wavefront's theme, “From Bit to Last Drop”, encompasses the life cycle of a client’s post exploration operations. Wavefront's primary focus areas are: performance drilling; well stimulation; and mature field revitalization.
WidePoint Corporation (WYY)
WidePoint Corporation is a leading provider of secured, cloud-based, enterprise-wide solutions and services for telecommunications life-cycle and cybersecurity management. WidePoint specializes in providing convergent solutions that optimize the benefits of Telecom Expense Management, Mobile Device Management, and Mobile Security Management with Identity and Access Management technologies and services. WidePoint enables Commercial Enterprises, State & Local Municipalities, and U.S Federal Agencies to deploy fully compliant information technology services in accordance with government mandated regulations and advanced system requirements meeting the highest standards of security and trust.
Wonder International Education & Investment Group Corp (WIEI)
Wonder is the first Chinese vocation school gone public in the USA. We provide a good learning environment that is conducive for students to master the practical vocational skills that they are interested in, despite their age, gender and current work situation. We teach them the skills to create value for themselves and the community and realize their professional dream. We are confident students will like our teaching staff and the modern facilities in our schools. After graduating from Wonder, our in house employment agency will even help our students find jobs.